2 Dividend Stocks That Are No-Brainer Buys in August

AbbVie’s Q2 revenue rose ~10% YoY to about $17B and adjusted EPS increased ~23% to $3.65, with the article highlighting dividend resilience while managing the upcoming patent cliffs (Humira already navigated; Skyrizi/Rinvoq next). Merck’s Q2 revenue grew ~5% YoY to $16.6B, with losses per share of $0.54 tied partly to acquisition-related expenses; growth at Keytruda (including subcutaneous Keytruda Qlex) was cited as $8.4B combined sales (+5% YoY) ahead of patent expiry in 2028. The piece frames both stocks as dividend “buy” candidates, noting Merck’s forward dividend yield of 2.5% and a 93.79% payout increase over a decade.

Analysis

The near-term winner is not just the two names, but the broader large-cap pharmaceutical complex versus high-duration growth. In a risk-off tape, ABBV and MRK should attract incremental capital from income funds and low-volatility mandates, while biotech indices and unprofitable healthcare names lose relative sponsorship. The second-order effect is multiple compression elsewhere in healthcare: if capital rotates into cash flow and dividends, names with weak balance sheets or no clear patent protection become funding sources.

ABBV looks structurally better positioned for the next 12-24 months because the market has already spent years underwriting its post-Humira reset; that usually reduces downside from incremental good news. MRK is cleaner on quality, but the market may be underestimating how much 2028 concentration risk can cap its multiple well before the cliff arrives, especially if pipeline readouts disappoint. The real issue is not current earnings stability, but whether management can keep dividend growth ahead of a looming revenue replacement burden without sacrificing capital allocation.

Contrarian view: the defensive dividend trade may be crowded and therefore less asymmetric than the article implies. If rates stay elevated or risk appetite improves, these stocks can lag because the market will prefer growth over yield, and their valuation support weakens. The catalyst that would reverse the thesis is a broad market rally plus any slip in immunology or oncology guidance; if ABBV loses pace on Skyrizi/Rinvoq growth or MRK shows any Keytruda deceleration, both can re-rate lower quickly over 1-3 months.

Key Decisions for Investors

• Prefer ABBV over MRK on a 3-6 month horizon: long ABBV / short MRK sized 1:1 as a patent-cliff timing pair, with upside if the market continues to reward nearer-term FCF visibility.
• If seeking defensive equity exposure, buy the pair on any broad market drawdown rather than chasing strength; both should outperform XBI and lower-quality biotech if volatility rises over the next 1-3 months.
• Sell upside in MRK rather than chasing dividend yield: consider covered calls into earnings if the stock rallies, because the 2028 Keytruda overhang can limit multiple expansion before pipeline proof points arrive.
• Watch for falsification: if either company cuts guidance or if channel checks show slowing immunology/oncology growth, exit the long quickly; the thesis is cash-flow durability, not narrative.